(CercleFinance.com) – Nanobiotix rose 4% this Monday on the Paris Stock Exchange after announcing new clinical results at the congress of the European Society of Oncology (ESMO).
The conclusions of a phase I study conducted in advanced pancreatic cancer show a median survival of 23 months in patients who received NBTXR3 injection, in combination with radiotherapy, compared to 19 months with radiotherapy alone.
In another phase I study, this time in head and neck cancer, patient survival was 43 months with NBTXR3 in addition to radiotherapy, compared to 18 months for radiotherapy alone.
NBTXR3 – the main project of the nanomedicine company – is a compound of hafnium nanoparticles which amplify by a factor of 9 the anti-tumor effect of radiotherapies.
It is currently the subject of around ten clinical trials, in partnership with institutions including Gustave Roussy and industrial groups such as Johnson & Johnson.